Post-earnings recap
Reported
Tue, Jul 21, 2026
EPS actual
$1.94
EPS est.
$1.83
EPS surprise
+5.72%
1-day move
-10.99%
Danaher Corporation reported an EPS of $1.94, exceeding expectations by 5.72%. However, the stock reacted negatively, dropping 10.99%. The lack of revenue details and management commentary may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.94 | N/A | +5.72% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
Danaher Corporation (DHR) operates in the health care sector, focusing on life sciences tools and services. The company plays a crucial role in providing innovative solutions that support research and diagnostics, making it significant in the ongoing advancements in health care and biotechnology.
Last quarter
In Q1-2026, Danaher reported an EPS of $2.06, beating expectations by 5.91%. However, the stock experienced a slight decline of 0.49% the following day, indicating mixed investor sentiment.
EPS beat streak
6Q
EPS beat rate
88%
Avg EPS surprise
+7.11%
Avg 1-day reaction
-2.40%
Investors are generally optimistic about Danaher's upcoming earnings, especially given its strong track record of beating EPS estimates. However, without specific guidance, there remains uncertainty about revenue performance.
Bull case
If Danaher continues its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products, leading to a positive market reaction.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in stock price, especially given the recent mixed performance.
The print will turn on these.
Q1
What will be the reported EPS for Q2-2026?
Given Danaher's history of beating EPS estimates, this number will be crucial for investor confidence and stock performance.
Q2
How does management view revenue growth in the current market environment?
Insights into revenue growth will help investors gauge the company's market position and future prospects.
—
Est. EPS
$0.41
Est. Rev
$318.0B
Impl. Move
±16.8%
Why consensus could be wrong
The Street may be underestimating Danaher's ability to capitalize on emerging health care trends, particularly in diagnostics and research tools.
Supporting evidence
Danaher has consistently beaten EPS estimates, suggesting stronger underlying demand than anticipated.
The options market is pricing in a larger move than historical averages, indicating potential for a significant reaction.
Recent performance trends in the health care sector suggest a rebound in demand for life sciences tools.
Key risk
If revenue growth comes in below expectations, it could undermine the positive EPS narrative.
Pre-commit to what would confirm each case.
The market is debating whether Danaher can maintain its growth momentum in a challenging economic environment.
Bull confirmed if
An EPS of $2.10 or higher would confirm the bull case and suggest strong demand.
Bear confirmed if
An EPS below $1.95 would validate the bear case and raise concerns about the company's growth trajectory.
What the market is pricing for the move.
Implied Move
±7.99%
Historical Avg
±5.1%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±8.0% while DHR has averaged ±5.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
29.5%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
84.41%
of float
Insider
10.96%
of float
Holders
2,859
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
55,084,630 sh · $12.0B
7.84%
6.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Danaher beats expectations, history suggests the stock could rise by around 0.98%, confirming strong demand.
In line / cautious
If results are in line with expectations but management is cautious, the stock may see limited movement as investors reassess future growth.
Miss
A miss could lead to a decline of approximately 9.73%, reflecting disappointment in the company's performance.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
41,377,076 sh · $9.0B
5.89%
0.6%
FMR, LLC
29,540,895 sh · $6.5B
4.20%
31.1%
State Street Corporation
28,456,019 sh · $6.2B
4.05%
2.0%
Wellington Management Group, LLP
16,316,834 sh · $3.6B
2.32%
10.4%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Aug 31, 2026 · disclosed Sep 25, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.